Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
60 Degrees Pharmaceuticals, Inc. (SXTP)
USD1.71
-0.04 (-2.29%)
US NASDAQ Healthcare Biotechnology
Address
1025 Connecticut Avenue NW 20036
Washington, DC, US
Washington, DC, US
CEO
Geoffrey Stuart Dow
Website
60degreespharma.com
IPO
2023-07-12
CIK 1946563 ISIN US83006G5009
Description
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.71
-0.04 (-2.29%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
124.3K
Beta
2.65
Float Shares
781.1K
Free Float %
96.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.79% | -10.90% | -21.91% | -56.70% | -65.93% | -31.53% | -85.02% | -99.88% | -99.88% | -99.88% | -99.88% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
1.71
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-12.80
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+65.5% ★ Q1'26: -0.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+84.2% ★ Q1'26: +79.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-733.4% Q1'26: -1,709.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-732.1% Q1'26: -1,292.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-942.0% Q1'26: -537.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+489.7% Q1'26: +437.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
253.6K
est: 250.0K (+1.4%)
|
607.6K
est: 600.0K (+1.3%)
|
1.01M
est: 1.40M (-28.2%)
|
1.90M
1.80M – 2.00M
+35.7% YoY
|
2.80M
2.74M – 2.86M
+47.4% YoY
|
3.90M
3.82M – 3.98M
+39.3% YoY
|
| EBITDA |
-1.43M
est: -201.5K (-607.8%)
|
-7.88M
est: -584.9K (-1,247.8%)
|
-7.28M
est: -1.36M (-433.2%)
|
-1.85M
-1.95M – -1.75M
-35.7% YoY
|
-2.73M
-2.79M – -2.67M
-47.4% YoY
|
-3.80M
-3.88M – -3.72M
-39.3% YoY
|
| EBIT |
-1.53M
est: -205.3K (-643.8%)
|
-7.95M
est: -592.4K (-1,241.6%)
|
-7.36M
est: -1.38M (-432.5%)
|
-1.88M
-1.97M – -1.78M
-35.7% YoY
|
-2.76M
-2.82M – -2.71M
-47.4% YoY
|
-3.85M
-3.93M – -3.77M
-39.3% YoY
|
| Net Income |
-3.77M
est: -43.09M (+91.3%)
|
-7.95M
est: -72.17M (+89.0%)
|
-7.37M
est: -7.87M (+6.3%)
|
-1.80M
-2.13M – -1.48M
+77.1% YoY
|
-1.45M
-1.49M – -1.41M
+19.7% YoY
|
-1.18M
-1.21M – -1.15M
+18.5% YoY
|
| SGA |
4.24M
est: 1.62M (+161.3%)
|
5.02M
est: 4.57M (+10.1%)
|
6.28M
est: 10.65M (-41.1%)
|
14.46M
13.70M – 15.22M
+35.7% YoY
|
21.31M
20.85M – 21.76M
+47.4% YoY
|
29.68M
29.04M – 30.31M
+39.3% YoY
|
| EPS |
-3.80
est: -94.80 (+96.0%)
|
-74.20
est: -107.68 (+31.1%)
|
-11.73
est: -11.74 (+0.1%)
|
-2.70
-3.17 – -2.21
+77.0% YoY
|
-2.16
-2.22 – -2.10
+19.9% YoY
|
-1.76
-1.81 – -1.71
+18.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-8.18M
OE per share TTM
-10.66
Owner's Yield
-340.83%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
12.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | KNIGHT THERAPEUTICS INC. | 1.11M | 19.90% | 1.11M | — | 1.11M | — | CO | CANADA | 2023-12-18 | ↗ |
| 2 | KNIGHT THERAPEUTICS INTERNATIONAL S.A. | 1.11M | 19.90% | 1.11M | — | 1.11M | — | CO | CANADA | 2023-12-18 | ↗ |
| 3 | Armistice Capital, LLC | 196.3K | 9.99% | — | 196.3K | — | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 4 | Steven Boyd | 196.3K | 9.99% | — | 196.3K | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
22.6K
Shares disposed
—
Cash buys
3.00
Cash sales
—
Net activity
+22,633
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-15 | DOW GEOFFREY S | Director / Officer | P-Purchase | A | Common Stock | 9,670 | 0.80 | 7.8K | 59,618 | D | ↗ |
| 2025-12-11 | DOW GEOFFREY S | Director / Officer | P-Purchase | A | Common Stock | 3,613 | 0.92 | 3.3K | 49,948 | D | ↗ |
| 2025-12-10 | DOW GEOFFREY S | Director / Officer | P-Purchase | A | Common Stock | 9,350 | 0.95 | 8.9K | 46,335 | D | ↗ |
| 2025-09-12 | DOW GEOFFREY S | Director / Officer | A-Award | A | Common Stock | 7,201 | 1.39 | 10.0K | 33,372 | D | ↗ |
| 2025-06-09 | DOW GEOFFREY S | Director / Officer | A-Award | A | Common Stock | 4,376 | 2.99 | 13.1K | 26,171 | D | ↗ |
| 2025-06-03 | XU CHERYL | Director | P-Purchase | A | Common Stock | 2,000 | 2.90 | 5.8K | 15,816 | D | ↗ |
| 2025-01-17 | MILLER TYRONE | Officer | A-Award | A | Common Stock | 11,626 | 0.00 | — | 26,370 | D | ↗ |
| 2025-01-17 | Landon Kristen | Officer | A-Award | A | Common Stock | 4,540 | 0.00 | — | 4,540 | D | ↗ |
| 2025-01-17 | DOW GEOFFREY S | Director / Officer | A-Award | A | Common Stock | 14,394 | 0.00 | — | 108,974 | D | ↗ |
| 2025-01-02 | MILLER TYRONE | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 1.31 | 98.3K | 75,000 | D | ↗ |
| 2025-01-02 | DOW GEOFFREY S | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 525,000 | 1.31 | 687.8K | 525,000 | D | ↗ |
| 2024-12-16 | XU CHERYL | Director | P-Purchase | A | Common Stock | 2,000 | 1.45 | 2.9K | 54,078 | D | ↗ |
| 2024-12-13 | XU CHERYL | Director | P-Purchase | A | Common Stock | 1,500 | 1.55 | 2.3K | 50,578 | D | ↗ |
| 2024-12-12 | XU CHERYL | Director | P-Purchase | A | Common Stock | 2,500 | 1.80 | 4.5K | 46,078 | D | ↗ |
| 2024-12-09 | DOW GEOFFREY S | Director / Officer | P-Purchase | A | Common Stock | 35,823 | 1.27 | 45.6K | 94,580 | D | ↗ |
| 2024-12-06 | DOW GEOFFREY S | Director / Officer | P-Purchase | A | Common Stock | 20,579 | 1.20 | 24.7K | 58,757 | D | ↗ |
| 2024-12-05 | DOW GEOFFREY S | Director / Officer | P-Purchase | A | Common Stock | 17,549 | 1.11 | 19.5K | 38,178 | D | ↗ |
| 2024-11-21 | DOW GEOFFREY S | Director / Officer | P-Purchase | A | Common Stock | 3,500 | 0.91 | 3.2K | 20,629 | D | ↗ |
| 2024-11-20 | DOW GEOFFREY S | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 0.92 | 924.30 | 17,129 | D | ↗ |
| 2024-11-19 | DOW GEOFFREY S | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 0.90 | 2.2K | 16,129 | D | ↗ |
| 2024-09-26 | Landon Kristen | Officer | A-Award | A | Stock Options (Right to Buy) | 4,167 | 6.85 | 28.5K | 4,167 | D | ↗ |
| 2024-08-27 | XU CHERYL | Director | P-Purchase | A | Common Stock | 5,000 | 1.70 | 8.5K | 41,078 | — | ↗ |
| 2024-02-12 | Landon Kristen | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-07-11 | Allen Charles W | Director | — | D | Restricted Stock Units | 8,000 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-24.5K
Shares Outstanding
806.6K
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Kristen Landon Chief Commercial Officer | 300.0K | 151.7K | — | 19.2K | — | — | 470.9K | 4.07% | ↗ |
| 2 | 2024 | Geoffrey Dow President and Chief Executive Officer (Principal Executive Officer) | 228.0K | 44.2K | — | 51.3K | — | — | 323.4K | 15.85% | ↗ |
| 3 | 2024 | Tyrone Miller Chief Financial Officer (Principal Financial and Accounting Officer) | 204.0K | 39.5K | — | 41.0K | — | — | 284.5K | 14.41% | ↗ |
| 4 | 2023 | Tyrone Miller Chief Financial Officer (Principal Financial and Accounting Officer) | 135.6K | — | — | — | — | — | 135.6K | 0.00% | ↗ |
| 5 | 2023 | Geoffrey Dow President and Chief Executive Officer (Principal Executive Officer) | 125.6K | — | — | — | — | — | 125.6K | 0.00% | ↗ |
| 6 | 2022 | Tyrone Miller Chief Financial Officer (Principal Financial and Accounting Officer) | 148.7K | — | — | — | — | — | 148.7K | 0.00% | ↗ |
| 7 | 2022 | Geoffrey Dow President and Chief Executive Officer (Principal Executive Officer) | 54.5K | — | — | — | — | — | 54.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kristen Landon | Chief Commercial Officer | 311.8K | female |
| Geoffrey Stuart Dow | Chairman, Chief Executive Officer & President | 250.0K | — |
| Tyrone Miller | Chief Financial Officer & Treasurer | 215.0K | male |
| Bryan Smith | Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SXTP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
